Clinical Trials · NCT06528210
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Withdrawn
- Sponsor
- OHSU Knight Cancer Institute
- Enrollment
- 0
- Start date
- Apr 2025
- Locations
- See registry
- Primary endpoint
- Biopsy-complete response determined by post-treatment biopsy